FDA Approves First Inhaled Mealtime Insulin for Children: A Needle-Free Option for Pediatric Diabetes

SAN FRANCISCO, May 29, 2026 — The U.S. Food and Drug Administration (FDA) has approved MannKind Corporation’s Afrezza (insulin human) inhalation powder for children and adolescents aged 6 years and older living with Type 1 and Type 2 diabetes. The milestone decision marks the first time a needle-free, rapid-acting mealtime insulin option has been made available to the pediatric population.

The regulatory milestone expands Afrezza’s use significantly beyond adults, where it has been an approved treatment option since June 2014. It offers a critical alternative to multiple daily injections for the estimated 304,000 children and adolescents across the United States who currently depend on insulin therapy to manage Type 1 diabetes. For families and young patients navigating the daily physical and psychological burdens of diabetes management, this newly approved delivery method could fundamentally reshape their daily care routines.

Key Findings from the Pivotal INHALE-1 Study

The FDA’s expanded approval was supported by data from the Phase 3 INHALE-1 clinical trial. This 26-week open-label, randomized study evaluated 230 pediatric patients aged 4 to 17 years diagnosed with Type 1 or Type 2 diabetes. All participants were actively utilizing a baseline injected basal insulin (long-acting insulin) and were randomly assigned to receive either inhaled Afrezza or traditional rapid-acting insulin analog injections at mealtimes.

The study’s primary endpoint focused on measuring changes in hemoglobin A1C—a standard blood test tracking average blood sugar levels over a three-month period—at the 26-week mark. The clinical data demonstrated that inhaled insulin provided glycemic control comparable to injected rapid-acting insulin, successfully establishing clinical non-inferiority.

INHALE-1 Study Trial Outcomes

“Inhaled insulin is the fastest acting insulin available and is a valuable alternative to injected analogue insulin,” noted Dr. Michael J. Haller, MD, MS-CI, professor and chief of pediatric endocrinology at the University of Florida and lead author of the INHALE-1 study. “Afrezza should be available as an option to all children and adults with Type 1 diabetes.”

How Inhaled Insulin Works

Unlike standard rapid-acting insulins that require subcutaneous injections (injections administered into the fatty layer just under the skin), Afrezza is administered directly through a small, portable inhaler right at the start of a meal.

The technology relies on MannKind’s proprietary Technosphere drug-delivery platform. This system utilizes microscopic particles that bind to insulin molecules, allowing the drug to dissolve instantly upon inhalation and pass through the lung membrane directly into the bloodstream.

Because it bypasses the slower absorption process of skin tissue, Afrezza features an ultra-rapid onset and a short duration of action. This closely mimics how a healthy pancreas naturally secretes insulin in response to food intake.

“For more than a century, insulin therapy for children living with diabetes has largely meant multiple daily injections,” said Michael Castagna, CEO of MannKind. “Children and their families deserve new treatment options that fit the realities of daily life. Afrezza allows dosing at the moment of eating, without the need for pre-meal planning, making it a practical option for unplanned meals and snacks on the go.”

Expert Commentary on Clinical Implications

Pediatric endocrinologists emphasize that an ultra-rapid, needle-free option holds substantial practical benefits for children, whose daily schedules and eating patterns are notoriously erratic.

“Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary,” explained Dr. Desmond Schatz, a professor of pediatrics at the University of Florida College of Medicine, who was not involved in the clinical trials. “With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option.”

The medical community has increasingly integrated alternative delivery methods into mainstream care. The American Diabetes Association (ADA) recognizes inhaled insulin within its official Standards of Care alongside multiple daily injection regimens and continuous insulin pumps, validating it as a reliable tool in the modern diabetes toolkit.

Safety Profile and Important Limitations

Despite the encouraging clinical trial outcomes, medical authorities emphasize that inhaled insulin is not a universal solution for all young patients. The packaging carries a prominent boxed warning regarding the risk of acute bronchospasm—a sudden constriction of the muscles in the walls of the bronchioles—in patients who have underlying chronic lung diseases.

Critical Safety and Administration Parameters:

• Contraindications: Afrezza is strictly contraindicated in pediatric patients with chronic lung conditions, including asthma or chronic obstructive pulmonary disease (COPD).

• Mandatory Screening: Pulmonary function testing (specifically FEV1, which measures the amount of air a person can force out of their lungs in one second) is required before initiating therapy, 6 months into treatment, and annually thereafter.

• Lifestyle Restrictions: It must not be used by patients who smoke or those who have quit smoking within the past 6 months.

• Condition Limits: The drug is not indicated for treating diabetic ketoacidosis (a life-threatening diabetes complication where the body produces excess blood acids).

The most common adverse reactions logged during pediatric trials included hypoglycemia (low blood sugar), throat pain or irritation, and a dry cough, which affected between 25.6% and 29.4% of participants.

Regarding long-term safety monitoring, clinical databases noted that lung cancer occurred in a few more patients taking Afrezza compared to those using other diabetes treatments. However, the total number of cases was too small to statistically determine if the medication was the direct cause.

“We saw no difference in lung function parameters over 26 weeks, and additional safety findings, including for hypoglycemia, revealed no significant concerns or differences between treatment groups,” countered Dr. Kevin Kaiserman, MD, Senior Vice President and Therapeutic Area Head of Endocrine Diseases at MannKind.

Accessibility, Cost, and Impact on Families

To address ongoing public concerns regarding the affordability of modern diabetes care, MannKind announced a dedicated access program alongside the pediatric launch. Qualifying patients will be able to obtain their monthly Afrezza prescription for $35 or less out-of-pocket, aiming to reduce financial friction for families managing the condition.

For parents, this approval introduces an essential choice, particularly for children experiencing acute needle anxiety or injection-related distress at school. It also provides a buffer for families managing highly unpredictable eating schedules.

However, parents must remember that children with a history of wheezing or asthma are entirely excluded from using this option, and scheduling baseline lung function tests remains a mandatory prerequisite.

Study Limitations and Future Directions

Independent researchers note that the INHALE-1 study carried a few notable design limitations. Because it was an open-label trial, both patients and physicians knew which treatment was being administered, which can introduce subtle bias. Additionally, the study’s primary non-inferiority margin was only narrowly met after researchers excluded one highly non-adherent participant from the final data analysis. Finally, a 26-week study timeline does not offer long-term tracking data concerning how inhaling insulin powder might affect developing pediatric lung tissue over several years or decades.

The official prescribing information explicitly states that it is not yet known whether Afrezza is completely safe and effective for children younger than 6 years old. To build on current data, MannKind has completed enrollment for a separate clinical trial evaluating the initiation of inhaled insulin immediately following a fresh Type 1 diabetes diagnosis in pediatric patients. Looking further ahead, investigators are exploring how inhaled insulin might eventually interact with automated insulin delivery systems, commonly known as “artificial pancreas” setups.

Ultimately, while the treatment requires careful screening and regular lung monitoring, this newly approved option offers pediatric endocrinologists and families an unprecedented, needle-free avenue to tailor diabetes care to a child’s lifestyle.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-mannkinds-inhaled-insulin-children-2026-05-29/